ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma
Abstract Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide, with late detection, ineffective treatment and poor overall survival. Immunotherapy, including immune checkpoint inhibitor (ICI) therapy, holds great potential for treatment of HCC. Although some patients respond...
Saved in:
Main Authors: | Xinyao Hu (Author), Dan Li (Author), Hua Zhu (Author), Tao Yu (Author), Xiaoxing Xiong (Author), Ximing Xu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment
by: Yingxi Du, et al.
Published: (2021) -
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
by: Huang Ao, et al.
Published: (2021) -
OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma
by: Yang An, et al.
Published: (2020) -
Immunotherapy in Hepatocellular Carcinoma
Published: (2023) -
Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023)